Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 5 versus DANAZOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 5 versus DANAZOL.
ANDROID 5 vs DANAZOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Danazol is a synthetic androgen derived from ethisterone that suppresses pituitary-ovarian axis by inhibiting gonadotropin release, leading to decreased estrogen and progesterone levels. It also has weak androgenic and progestational activity.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
300-600 mg orally twice daily; maximum 800 mg/day
None Documented
None Documented
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Clinical Note
moderateDanazol + Tolbutamide
"The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Rosiglitazone
"The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Pioglitazone
"The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Saxagliptin
Terminal elimination half-life is 4-4.5 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Primarily hepatic metabolism; approximately 60% excreted in feces, 30% in urine as metabolites.
Category C
Category C
Androgen
Androgen/Antigonadotropin
"The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Danazol."